BioStem Technologies, Inc., a regenerative medicine company specializing in perinatal tissue allograft products, has filed its audited consolidated financial statements for the fiscal years ended December 31, 2024 and 2025. The company, trading on the OTC Markets under the symbol BSEM, stated that this publication represents a significant step toward its planned uplisting to the Nasdaq stock exchange. The financial documents are available for public review on the OTC Markets website.
Jason Matuszewski, Chairman and CEO of BioStem Technologies, emphasized the importance of this milestone. He noted that alongside recent appointments of a new chief financial officer, auditor, and audit committee chair, the publication demonstrates the company's commitment to establishing robust financial reporting processes. Matuszewski stated that listing on Nasdaq remains a top corporate priority, as it would increase the company's visibility, improve stock liquidity, provide a more precise market valuation, and enhance its ability to attract top talent.
BioStem Technologies focuses on developing, manufacturing, and commercializing advanced allograft solutions derived from perinatal tissue. The company utilizes proprietary processing technologies—BioRetain®, CryoTek®, and SteriTek®—designed to preserve the natural properties of these tissues for clinical use. Its products are employed by clinicians across various medical specialties. The company's quality management system and standard operating procedures have been accredited by the American Association of Tissue Banks and comply with current Good Tissue Practices and current Good Manufacturing Processes.
The company's product portfolio includes the Neox®, Clarix®, VENDAJE®, and American Amnion™ brands. BioStem maintains a national commercial footprint and is engaged in expanding clinical research initiatives within the regenerative medicine field. Additional information about the company is available at its official website, biostemtechnologies.com.
The publication of audited financial statements is a critical requirement for companies seeking to uplist from over-the-counter markets to major exchanges like Nasdaq. For BioStem, this move could potentially broaden its investor base, increase trading volume, and lend greater credibility within the biomedical sector. Enhanced visibility on a national exchange may also support the company's commercial growth and research endeavors by facilitating access to capital and strategic partnerships. The announcement reflects BioStem's ongoing efforts to strengthen its corporate governance and financial transparency as it positions itself for future growth in the competitive regenerative medicine market.
